Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SX-682 in Myelodysplastic Syndromes
NCT04245397Phase 1Recruiting
- Sponsor
- Syntrix Pharmaceuticals
- Start
- Jun 2020
- Primary completion
- Mar 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of SX-682 in myelodysplastic syndrome (MDS) (8 arms), sponsored by Syntrix Pharmaceuticals. Primary endpoints: Maximum Tolerated Dose at 28 days, Dose Limiting Toxicities at 28 days and 1 more. Started Jun 2020; status: recruiting.
02
Drugs
SX-682
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT04245397.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04245397.